{
  "docId": "019de071-eb84-776b-8e7d-ce40a476afec",
  "docSlug": "ee62a94395a2a2b10c5eb93465b3bf02",
  "documentTitle": "Kymera | Investor Day Presentation Deck | 105 slides",
  "authorId": "kymera",
  "authorName": "Kymera",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 77,
  "pageCount": 105,
  "prevPage": 76,
  "nextPage": 78,
  "slideType": "propose_solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a biological pathway diagram to contrast two therapeutic modalities (inhibitor vs. degrader) in the context of p53 regulation.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-eb84-776b-8e7d-ce40a476afec/77",
  "deckHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec",
  "deckJsonHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec.json",
  "deckAnchorHref": "/decks/019de071-eb84-776b-8e7d-ce40a476afec#slide-77",
  "components": [
    {
      "bbox": {
        "h": 0.75,
        "w": 0.48,
        "x": 0.03,
        "y": 0.15
      },
      "kind": "diagram",
      "text": "Biological pathway showing stressor-induced p53 activation, MDM2 feedback loop, and the impact of inhibitors vs. degraders.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0235987b-6850-4d33-a996-43bef456efcc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.75,
        "w": 0.44,
        "x": 0.53,
        "y": 0.15
      },
      "kind": "list",
      "text": "Clinical Validation: MDM2 small molecule inhibitors show activity but induce feedback loops. Degrader Advantage: MDM2 degraders remove the protein, overcoming feedback and increasing efficacy.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "69f97dde-33bf-4bf5-8274-cb2a94916e14",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.82,
        "x": 0.09,
        "y": 0.04
      },
      "kind": "title",
      "text": "MDM2 Degradation, Not Inhibition, Efficiently Restores p53",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9d509089-e8e2-4b99-991b-2880d43a9290",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "before-after-framing",
      "slug": null,
      "matchId": "844597f9-757e-4a45-8e4d-d40f5618cda0",
      "evidence": "Contrasts the 'before' state (inhibitor/feedback loop) with the 'after' state (degrader/restored p53).",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 84,
      "from": 76,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "baf11c7b-bcf3-45f9-a0f0-de730275483d",
      "evidence": "The deck presents the limitations of current approaches and the benefits of Kymera's MDM2 degrader.",
      "position": 1,
      "objective": "To highlight the potential consequences of not adopting TPD, specifically in the context of MDM2 and p53.",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}